Evidence map›Paper›PMID 37848674›Full record

ArticleApoptosis : an international journal on programmed cell death2024

High pyroptosis activity in pancreatic adenocarcinoma: poor prognosis and oxaliplatin resistance.

Guangfu Wang, Jin Chen, Shangnan Dai, Jinfan Zhang, Yong Gao, Lingdi Yin, Kuirong Jiang, Yi Miao, Zipeng Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Guangfu Wang *Pancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jin Chen *Department of Gynecological Oncology, Jiangsu Cancer Hospital, Nanjing, China.
Shangnan Dai *Pancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jinfan ZhangPancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yong GaoPancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lingdi YinPancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Kuirong JiangPancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi MiaoPancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. miaoyi@njmu.edu.cn.
Zipeng LuPancreas Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. surgeonmark@hotmail.com.
Nanjing Medical University · CNJiangsu Cancer Hospital · CNJiangsu Province Hospital · CN

Funding

Clinical Science and Technology Climbing program - "Spark" basic research project ZJ202124Construction Program of Jiangsu Provincial Clinical Research Center Support System BL2014084National Natural Science Foundation of China 82173206National Natural Science Foundation of China 82272974Natural Science Foundation of Jiangsu Province BK20221416Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent JCRCA2016009
6 · The paper itself

Abstract

backgroundPyroptosis, as a type of inflammatory programmed cell death, has been studied in inflammatory diseases and numerous cancers but its role in pancreatic ductal adenocarcinoma (PDAC) remains further exploration.

methodsA TCGA-PDAC cohort was enrolled for bioinformatics analysis to investigate the effect of pyroptosis on the prognosis and drug sensitivity of patients. PA-TU-8988T and CFPAC-1 cells were selected for investigating the role of GSDMC in PDAC.

resultsA distinct classification pattern of PDAC mediated by 21 pyroptosis-related genes (PRGs) was identified. It was suggested that higher pyroptosis activity was associated with poor prognosis of patients and higher tumor proliferation rates. We further established a prognostic model based on three PRGs (GSDMC, CASP4 and NLRP1) and the TCGA-PDAC cohort was classified into low and high-risk subgroups. It is noteworthy that the high-risk group showed significantly higher tumor proliferation rates and was proved to be highly correlated with oxaliplatin resistance. Further experiments suggested that overexpression of GSDMC promoted the proliferation and oxaliplatin resistance of PA-TU-8988T cells in vitro and vivo, while downregulation of GSDMC showed opposite effects in CFPAC-1 cells. Finally, we found that the activation of pentose phosphate pathway (PPP) was the mechanism by which GSDMC overexpression promoted the proliferation and oxaliplatin resistance of pancreatic cancer cells.

conclusionsIn this study, we found that higher pyroptosis activity is associated with worse prognosis and oxaliplatin resistance of PDAC patients. In addition, as a core effector of pyroptosis, GSDMC promoted proliferation and oxaliplatin resistance of pancreatic cancer cells, which will provide new therapeutic target for PDAC patients.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsApoptosisBiomarkers, TumorCell Line, TumorCell ProliferationGasderminsHumansOxaliplatinPyroptosisBiomarkers, TumorGasderminsGSDMC protein, humanOxaliplatinGSDMCOxaliplatinPentose phosphate pathwayProliferation

Identifiers

PMID37848674
OpenAlexW4387700252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.